Navigation Links
Teva Respiratory Supports World Asthma Day by Providing FREE QVAR(R) to Those Who Need It Most

NORTH WALES, Pa., May 5 /PRNewswire/ -- In support of World Asthma Day, May 5, 2009, Teva Respiratory has extended its partnership with Direct Relief International, a nonprofit humanitarian medical relief organization, to donate thousands of units of QVAR(R) (Beclomethasone HFA), an Inhaled Corticosteroid (ICS) to its Charitable Medicine Access Program. Direct Relief will distribute the medication to economically disadvantaged and uninsured patients through the National Association of Community Health Centers (NACHC) and the National Association of Free Clinics (NAFC).

Earlier in the year, Teva Respiratory donated several hundred thousand units of ProAir(R) HFA (albuterol sulfate) Inhalation Aerosol fast-relief albuterol-metered dose inhalers (MDIs) to Direct Relief providing patients with life-saving medication they may not have received otherwise. As the number of uninsured U.S. citizens continues to rise, donations of this kind become paramount.

"The initial ProAir(R) donation ensured that patients had access to rescue inhalers, a critical part of the comprehensive treatment plan for asthma, during an important time in the market - the transition to environmentally friendly, HFA inhalers. With the additional QVAR donation, we can now ensure that patients have full asthma control and the ability to manage the underlying cause of the disease--inflammation," said Mark Salyer, General Manager of Teva's Respiratory Division. "We recognize that access to treatment is an issue for many patients and we are committed to asthma care and ensuring that patient needs are met."

Direct Relief, NACH and NAFC together identify health clinics where the need is greatest - where the majority of patients cannot afford to pay for their medication -- and distribute the inhalers accordingly. This process ensures greater patient access to medication, reduces the administrative burden associated labor costs, and provides for better patient outcomes.

"Teva Respiratory's donation of ProAir(R) and QVAR(R) will help hundreds of thousands of people who have a serious respiratory condition that, left untreated, could put them in the hospital," said Thomas Tighe, President and CEO of Direct Relief International. "Not only does Teva's generosity help patients, but it helps the recipient clinics, who are themselves under strain from recession-induced increases in patient loads, making the donation even more important."

Direct Relief International

Founded in 1948, Direct Relief International is a Santa Barbara-based nonprofit organization focused on improving the quality of life by bringing critically needed medicines and supplies to local healthcare providers worldwide. Direct Relief works in 59 countries and has delivered more than $1 billion in privately funded humanitarian medical aid to health professionals serving impoverished communities since 2000. Direct Relief is one of two charities ranked by Forbes that has received a perfect fundraising efficiency score for five consecutive years and is ranked by the Chronicle of Philanthropy as California's largest international nonprofit organization based on private support. For more information, please visit

About the National Association of Community Health Centers (NACHC)

To address the widespread lack of access to basic health care, Community Health Centers serve 18 million people at more than 7,000 sites located throughout all 50 states and U.S. territories. Health centers depend in large part on public financial help and need a unified voice and common source for research, information, training and advocacy. To address these needs, the National Association of Community Health Centers (NACHC) organized in 1971. NACHC works with a network of state health center and primary care organizations to serve health centers in a variety of ways, including to provide research-based advocacy for health centers and their clients; educate the public about the mission and value of health centers; train and provide technical assistance to health center staff and boards; and develop alliances with private partners and key stakeholders to foster the delivery of primary health care services to communities in need. For more information, please visit

About the National Association of Free Clinics (NAFC)

NAFC is the only national nonprofit whose mission is solely focused on the needs of free clinics and the populations they serve. Founded in 2001 by Free Clinic leaders from across the country, the NAFC supports community-based, nonprofit, volunteer-supported Free Clinics serving the uninsured and underinsured. The leadership of the NAFC focuses on bringing advocacy, networking, and needed resources to free clinics to help them face their many challenges. The NAFC estimates that Free Clinics raise over $300 million per year in private funds, which are used to provide care for approximately 3.5 million uninsured and underinsured patients, and generate $3 billion in health care services.

About Teva Respiratory

Teva Respiratory is the U.S.-based respiratory division of Teva Pharmaceuticals Industries Ltd. Teva Pharmaceuticals Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Europe.

ProAir(R) HFA

ProAir(R) HFA is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Important Safety Information

If your symptoms become significantly worse when you use ProAir(R) HFA, contact your doctor immediately. This may indicate either a worsening of your asthma or a reaction to the medication, which may rarely occur with the first use of a new canister of ProAir(R) HFA. Either of these could be life-threatening.

What to tell your doctor before using ProAir(R) HFA: If you have a heart, blood, or seizure disorder, high blood pressure, diabetes, or an overactive thyroid, be sure to tell your doctor. Also make sure your doctor knows all medications you are taking--especially heart medications and drugs that treat depression--because some medications may interfere with how well your asthma medications work. Do not exceed the recommended dose.

Side effects associated with ProAir(R) HFA include headache, rapid heart beat, pain, dizziness, and irritation of the throat and nose.


QVAR(R) is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older.

QVAR(R) is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR(R) may reduce or eliminate the need for systemic corticosteroids.

Important Safety Information

QVAR(R) does not replace fast-acting (rescue) inhalers for sudden symptoms.

If you are switching from an oral corticosteroid to QVAR(R), follow your doctor's instructions to avoid health risks when you stop using oral corticosteroids.

Inhaled corticosteroids may cause a reduction in growth rate. The long-term effect on final adult growth is unknown.

In clinical studies, common side effects included headache and pharyngitis.

Do not stop taking QVAR(R) abruptly without talking to your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit:, or call 1-800-FDA-1088.

SOURCE Teva Respiratory
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Number of Revascularization Procedures, Related In-Hospital Mortality and Some Complications Decline, While Rates of Infection and Acute Respiratory Distress Syndrome (ARDS) Following Coronary Artery Bypass Graft (CABG) Surgery Increase
2. Council for Quality Respiratory Care Applauds President Obamas Appointments of Governor Sebelius, DeParle to Lead Health Care Efforts
3. Broccoli may help protect against respiratory conditions like asthma
4. Global Warming May Bring More Respiratory Woes
5. Global warning: Hotter days, increased hospitalizations for respiratory problems
6. PARI Respiratory Equipment Launches 2 New Continuing Ed Classes
7. Acute Respiratory Distress Syndrome as Deadly as Ever
8. Popular cold and cough treatment may create respiratory distress in young children
9. A Principled Approach to Medical Mistakes To Be Addressed at 54th Annual International Congress for Respiratory Therapists
10. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
11. Hospital visits for respiratory illnesses spiked during Southern California wildfires
Post Your Comments:
(Date:5/26/2016)... ... May 26, 2016 , ... ... for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 ... , Dr. Maisel, founder of Retina Group of New York , is ...
(Date:5/26/2016)... , ... May 26, 2016 , ... In an effort to provide hair restoration information ... both Snapchat users and those who do not use the app. Dr. Mohebi, the founder ... page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response to ...
(Date:5/26/2016)... ... 26, 2016 , ... Leadership of Life Science Logistics (LSL), ... has earned its ISO 13485 certification, indicating the company’s quality control system for ... policies associated with ISO quality standard 13485. , BSI Group America, Inc., ...
(Date:5/26/2016)... ... 2016 , ... The Lung Institute has partnered with the Gulfcoast ... June 6 at their clinic in downtown Tampa. The class is complimentary for the ... has created a free downloadable 4 Week Smoking Cessation Guide for those ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... offering campers a multitude of activities from daily practices, arts & crafts, discussions, ... Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
(Date:5/25/2016)... , May 25, 2016 According ... Share, Development, Growth and Demand Forecast to 2022 - ... Pump and Others)" published by P&S Market Research, the ... million in 2015, and it is expected to grow ... type, the insulin pump segment is expected to witness ...
(Date:5/25/2016)... , May 25, 2016 MedDay, a ... announces that an oral presentation entitled "High doses of biotin ... trial" will be given by Professor Ayman Tourbah , ... Congress of the European Academy of Neurology (EAN) in ... related disorders 3" will take place on Sunday, 29 May ...
Breaking Medicine Technology: